SK231292A3 - Proteins - Google Patents

Proteins Download PDF

Info

Publication number
SK231292A3
SK231292A3 SK2312-92A SK231292A SK231292A3 SK 231292 A3 SK231292 A3 SK 231292A3 SK 231292 A SK231292 A SK 231292A SK 231292 A3 SK231292 A3 SK 231292A3
Authority
SK
Slovakia
Prior art keywords
lys
restrictocin
natural
alpha
cys
Prior art date
Application number
SK2312-92A
Other languages
English (en)
Slovak (sk)
Inventor
John E Fitton
David Timms
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919116011A external-priority patent/GB9116011D0/en
Priority claimed from GB919116000A external-priority patent/GB9116000D0/en
Priority claimed from GB919116002A external-priority patent/GB9116002D0/en
Priority claimed from GB919115999A external-priority patent/GB9115999D0/en
Priority claimed from GB919116001A external-priority patent/GB9116001D0/en
Priority claimed from GB929207488A external-priority patent/GB9207488D0/en
Priority claimed from GB929208397A external-priority patent/GB9208397D0/en
Application filed by Ici Plc filed Critical Ici Plc
Publication of SK231292A3 publication Critical patent/SK231292A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6831Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
SK2312-92A 1991-07-24 1992-07-23 Proteins SK231292A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB919116011A GB9116011D0 (en) 1991-07-24 1991-07-24 Proteins
GB919116000A GB9116000D0 (en) 1991-07-24 1991-07-24 Proteins
GB919116002A GB9116002D0 (en) 1991-07-24 1991-07-24 Proteins
GB919115999A GB9115999D0 (en) 1991-07-24 1991-07-24 Proteins
GB919116001A GB9116001D0 (en) 1991-07-24 1991-07-24 Proteins
GB929207488A GB9207488D0 (en) 1992-04-06 1992-04-06 Proteins
GB929208397A GB9208397D0 (en) 1992-04-16 1992-04-16 Proteins

Publications (1)

Publication Number Publication Date
SK231292A3 true SK231292A3 (en) 1995-03-08

Family

ID=27562864

Family Applications (1)

Application Number Title Priority Date Filing Date
SK2312-92A SK231292A3 (en) 1991-07-24 1992-07-23 Proteins

Country Status (14)

Country Link
US (1) US5439815A (cs)
EP (1) EP0524768B1 (cs)
JP (1) JPH05292960A (cs)
AT (1) ATE166389T1 (cs)
AU (1) AU654563B2 (cs)
CA (1) CA2070751A1 (cs)
CZ (1) CZ231292A3 (cs)
DE (1) DE69225539T2 (cs)
FI (1) FI923311A7 (cs)
HU (1) HUT66110A (cs)
IE (1) IE922135A1 (cs)
IL (1) IL102389A0 (cs)
NO (1) NO922933L (cs)
SK (1) SK231292A3 (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248606A (en) * 1990-06-11 1993-09-28 Dowelanco Dna encoding inactive precursor and active forms of maize ribosome inactivating protein
GB9304905D0 (en) * 1992-03-16 1993-04-28 Zeneca Ltd Processes
IT1286663B1 (it) * 1996-06-27 1998-07-15 Ministero Uni Ricerca Scient E Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
US6262231B1 (en) * 1998-03-24 2001-07-17 Council Of Scientific And Industrial Research Polypeptides useful for diagnosis of Aspergillus fumigatus and a process of preparing the same
ES2241383B2 (es) * 2002-03-08 2008-04-01 Universidad Complutense De Madrid Metodo de produccion de variantes de ribotoxina.
US6878531B1 (en) * 2003-11-10 2005-04-12 Medical College Of Georgia Research Institute Method for multiple site-directed mutagenesis
CN101371140B (zh) * 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
WO2014158770A1 (en) * 2013-03-14 2014-10-02 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
WO2017053290A1 (en) * 2015-09-23 2017-03-30 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3104208A (en) * 1963-09-17 Restkictocin
US3104204A (en) * 1960-07-11 1963-09-17 Michigan State Alpha sarcin
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
WO1988007578A1 (en) * 1987-04-02 1988-10-06 Genentech, Inc. Substrate assisted catalysis
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ES2154627T3 (es) * 1988-08-24 2001-04-16 American Cyanamid Co Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JP2518732B2 (ja) * 1990-02-22 1996-07-31 株式会社大塚製薬工場 α―サルシン遺伝子
GB9304905D0 (en) * 1992-03-16 1993-04-28 Zeneca Ltd Processes

Also Published As

Publication number Publication date
IE922135A1 (en) 1993-01-27
HUT66110A (en) 1994-09-28
AU654563B2 (en) 1994-11-10
EP0524768A2 (en) 1993-01-27
FI923311A0 (fi) 1992-07-20
FI923311L (fi) 1993-01-25
US5439815A (en) 1995-08-08
DE69225539D1 (de) 1998-06-25
CA2070751A1 (en) 1993-01-25
AU1866892A (en) 1993-01-28
HU9202343D0 (en) 1992-10-28
CZ231292A3 (en) 1993-04-14
EP0524768B1 (en) 1998-05-20
NO922933L (no) 1993-01-25
JPH05292960A (ja) 1993-11-09
IL102389A0 (en) 1993-01-14
NO922933D0 (no) 1992-07-23
ATE166389T1 (de) 1998-06-15
FI923311A7 (fi) 1993-01-25
EP0524768A3 (cs) 1994-02-09
DE69225539T2 (de) 1998-10-22

Similar Documents

Publication Publication Date Title
JP2567385B2 (ja) 神経突起促進因子及びその製造方法
EP0335243B1 (en) Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
JP2526965B2 (ja) ムテイン,dnaおよびその用途
EP0673417A1 (en) LIGAND BINDING VARIABLE DOMAIN (V-MIN) COMPRISING A FRAMEWORK REGION WITH A CYCLICALLY PERMUTED CENTRAL $g(b)-BARREL
HUT64582A (en) Method for producing recombinant human interleukin-1 inhibitor
CA2066370C (en) Yield when disulfide-bonded proteins are secreted
JPH10500298A (ja) 三量体化ポリペプチド、その製造及び使用
JPH01501283A (ja) 新規な型のコロニー刺激因子―1
Engel et al. Murein-metabolizing enzymes from Escherichia coli: existence of a second lytic transglycosylase
Kozutsumi et al. Identification of immunoglobulin heavy chain binding protein as glucose-regulated protein 78 on the basis of amino acid sequence, immunological cross-reactivity, and functional activity
JPH09503751A (ja) 細胞毒性抱合体の単一起源性製剤
JP2002300890A (ja) 組換えヤドリギレクチン(rML)
CZ231292A3 (en) Proteins
Wang et al. Recombinant bovine α-lactalbumin obtained by limited proteolysis of a fusion protein expressed at high levels in Escherichia coli
NO174970B (no) Rekombinant DNA, rekombinant DNA-vektor samt vertscelle
JPH07507926A (ja) サポリン含有タンパク質の組換え産生
US4948729A (en) Production of soluble recombinant proteins
JP3310672B2 (ja) シグナルペプチドを有さないスタフィロキナーゼの発現
King et al. Isolation, expression, and characterization of fully functional nontoxic BiP/GRP78 mutants
JP3364972B2 (ja) 魚由来トランスグルタミナーゼ遺伝子
JP3010360B2 (ja) 組換リシントキシン
US5852177A (en) Basic fibroblast growth factor (bFGF) muteins
EP0230781A2 (en) Lymphotoxin gene, method for its production, and lymphotoxin
US5306626A (en) Process for production of restrictocin
JPS60502136A (ja) 微生物によるインタ−ル−キン2の形質発現